Groland bets on AI-driven scalp health to fuel hair growth

Groland said June 8, 2026, that it is pushing hair care toward a scalp-first model built on AI-designed molecular actives, clinical testing, and scalp-aging research. The company’s new AquaKine Scalp Serum is positioned as a dual-action product that targets follicle activation and scalp structural support.

Why it matters: - Groland is pitching scalp health as the biological foundation for sustainable hair growth, not just a cosmetic add-on. - The company is targeting a market that increasingly links hair thinning to inflammation, barrier decline, microbiome imbalance and follicular aging. - The approach matters because it could shift scalp care from short-term soothing products to long-term molecular intervention.

What happened: - Groland introduced its AquaKine Scalp Serum on June 8, 2026, from China. - The launch centers on an AI-driven molecular platform for scalp wellness and hair growth. - Groland says the company was built around a scalp-wellness model from the start. - The company’s R&D center is based in Boston and is built on MIT’s scientific foundation. - Groland says it uses XtalPi’s AI-driven biotechnology platform for product discovery.

The details: - Groland’s development system combines AI screening, molecular prediction and precision validation. - The company says the platform cuts R&D timelines to about one-third of conventional cosmetic cycles and improves development efficiency by more than 40 times. - The serum’s proprietary “Gemini” molecular system includes Remeanagen (XTP-118) and AquaKine Peptide (XTP-016). - Both molecules have assigned INCI names, which Groland frames as a milestone for AI-designed cosmetic actives. - Remeanagen is positioned as a follicle-reactivation molecule and a novel AMPK agonist that activates autophagy. - Groland says experimental data showed ATP increased to 129.23% with Remeanagen. - AquaKine Peptide is designed to strengthen the scalp environment by promoting collagen synthesis. - Groland says testing showed increases of up to 248.78% in type I collagen, 178.18% in type III, 165.91% in type V and 175.93% in type XVII. - Groland cites a 2016 Science study on COL17A1 loss and follicular stem cell depletion as part of the scientific basis for its approach. - The company says the dual system is intended to reactivate dormant follicles while reinforcing the scalp structure that supports them. - Independent third-party testing on AquaKine Scalp Serum showed a 14-day improvement in scalp elasticity, firmness and texture quality. - The same 14-day evaluation showed sebum secretion fell by 58.16%, scalp redness and barrier-related indicators improved by 43.94%, and root strength and hair volumizing performance rose by 14.17%. - In a separate six-week study of 32 participants, hair density increased by 21.21%, the anagen-phase hair ratio rose by 9.09% and average hair shaft count per follicular unit improved by 9.74%. - The six-week study also showed sebum levels down 29.58%, transepidermal water loss down 17.49% and scalp hydration and elasticity up 89.64%. - Raman spectroscopy found a 9.12% relative penetration rate within 4 hours and a penetration depth of 115 microns, compared with benchmark products at 7.25% and 80 microns. - Groland says multiple irritation tests found the serum mild and non-irritating, and 63 hormonal substances were not detected. - The article includes references to five published studies on autophagy, hair follicle regeneration and hair growth biology.

Between the lines: - Groland is trying to frame hair loss as a scalp-aging problem, which is a broader and more science-forward pitch than traditional anti-hair-loss marketing. - The company is also using AI and pharmaceutical-style language to differentiate itself from typical cosmetic brands. - The clinical claims are presented as support for a long-term scalp-longevity thesis, not just a faster-growth promise.

What’s next: - Groland appears to be betting that future hair-care growth will come from brands built specifically around scalp biology. - The company is positioning itself to compete in a category where molecular design and clinical validation may matter more than familiar cosmetic ingredients. - The broader test for Groland will be whether consumers and the market treat scalp wellness as a core hair-growth category, not a niche concept.

The bottom line: - Groland is making a clear wager that the next wave of hair-growth innovation starts with the scalp ecosystem, not the hair strand.